Skip to Content

Ceftin (cefuroxime) Disease Interactions

There are 7 disease interactions with Ceftin (cefuroxime):

Major

Antibiotics (Includes Ceftin) ↔ colitis

Severe Potential Hazard, Moderate plausibility. Applies to: Colitis/Enteritis (Noninfectious)

Pseudomembranous colitis has been reported with most antibacterial agents and may range in severity from mild to life-threatening, with an onset of up to two months following cessation of therapy. Antibiotic therapy can alter the normal flora of the colon and permit overgrowth of Clostridium difficile, whose toxin is believed to be a primary cause of antibiotic- associated colitis. The colitis is usually characterized by severe, persistent diarrhea and severe abdominal cramps, and may be associated with the passage of blood and mucus. The most common culprits are clindamycin, lincomycin, the aminopenicillins (amoxicillin, ampicillin), and the cephalosporins. Therapy with broad-spectrum antibiotics and other agents with significant antibacterial activity should be administered cautiously in patients with a history of gastrointestinal diseases, particularly colitis. There is some evidence that pseudomembranous colitis, if it occurs, may run a more severe course in these patients and that it may be associated with flares in their underlying disease activity. The offending antibiotic(s) should be discontinued if significant diarrhea occurs during therapy. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically. A large bowel endoscopy may be considered to establish a definitive diagnosis in cases of severe diarrhea.

References

  1. Moriarty HJ, Scobie BA "Pseudomembranous colitis in a patient on rifampicin and ethambutol." N Z Med J 04/23/80 (1980): 294-5
  2. Thomas E, Mehta JB "Pseudomembranous colitis due to oxacillin therapy." South Med J 77 (1984): 532-3
  3. Saadah HA "Carbenicillin and pseudomembranous enterocolitis." Ann Intern Med 93 (1980): 645
  4. Daly JJ, Chowdary KV "Pseudomembranous colitis secondary to metronidazole." Dig Dis Sci 28 (1983): 573-4
  5. Lyon JA "Imipenem/cilastatin: the first carbapenem antibiotic." Drug Intell Clin Pharm 19 (1985): 894-8
  6. Trexler MF, Fraser TG, Jones MP "Fulminant pseudomembranous colitis caused by clindamycin phosphate vaginal cream." Am J Gastroenterol 92 (1997): 2112-3
  7. O'Meara TF, Simmons RA "Carbenicillin and pseudomembranous enterocolitis." Ann Intern Med 92 (1980): 440-1
  8. Meadowcroft AM, Diaz PR, Latham GS "Clostridium difficile toxin-induced colitis after use of clindmycin phosphate vaginal cream." Ann Pharmacother 32 (1998): 309-11
  9. Bauwens JE, McFarland LV, Melcher SA "Recurrent clostridium difficile disease following ciprofloxacin use." Ann Pharmacother 31 (1997): 1090
  10. Dan M, Samra Z "Clostridium difficile colitis associated with ofloxacin therapy." Am J Med 87 (1989): 479
  11. Davies J, Beck E "Recurrent colitis following antibiotic-associated pseudomembranous colitis." Postgrad Med J 57 (1981): 599-601
  12. Cone JB, Wetzel W "Toxic megacolon secondary to pseudomembranous colitis." Dis Colon Rectum 25 (1982): 478-82
  13. Cannon SR, Dyson PH, Sanderson PJ "Pseudomembranous colitis associated with antibiotic prophylaxis in orthopaedic surgery." J Bone Joint Surg Br 70-B (1988): 600-2
  14. Miller DL, Sedlack JD, Holt RW "Perforation complicating rifampin-associated pseudomembranous enteritis." Arch Surg 124 (1989): 1082
  15. Miller SN, Ringler RP "Vancomycin-induced pseudomembranous colitis." J Clin Gastroenterol 9 (1987): 114-5
  16. Wang C, Calandra GB, Aziz MA, Brown KR "Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience." Rev Infect Dis 7 (1985): s528-36
  17. Harmon T, Burkhart G, Applebaum H "Perforated pseudomembranous colitis in the breast-fed infant." J Pediatr Surg 27 (1992): 744-6
  18. Pokorney BH, Nichols TW, Jr "Pseudomembranous colitis. A complication of sulfasalazine therapy in a patient with Crohn's colitis." Am J Gastroenterol 76 (1981): 374-6
  19. Milstone EB, McDonald AJ, Scholhamer CF Jr "Pseudomembranous colitis after topical application of clindamycin." Arch Dermatol 117 (1981): 154-5
  20. Bernstein L "Adverse reaction to trimethoprim-sulfamethoxazole, with particular reference to long-term therapy." Can Med Assoc J 112 (1975): s96-8
  21. Ehrenpreis ED, Lievens MW, Craig RM "Clostridium difficile-associated diarrhea after norfloxacin." J Clin Gastroenterol 12 (1990): 188-9
  22. Sankarankutty M, McGeorge D, Galasko CS "Pseudomembranous colitis following cephradine prophylaxis." Postgrad Med J 58 (1982): 726-8
  23. Gordin F, Gibert C, Schmidt ME "Clostridium difficile colitis associated with trimethoprim-sulfamethoxazole given as prophylaxis for pneumocystis carinii pneumonia." Am J Med 96 (1994): 94-5
  24. Osler T, Lott D, Bordley J, et al "Cefazolin-induced pseudomembranous colitis resulting in perforation of the sigmoid colon." Dis Colon Rectum 29 (1986): 140-3
  25. Parry MF, Rha CK "Pseudomembranous colitis caused by topical clindamycin phosphate." Arch Dermatol 122 (1986): 583-4
  26. Clissold SP, Todd PA, Campoli-Richards DM "Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy." Drugs 33 (1987): 185-241
  27. Van Ness MM, Cattau EL Jr "Fulminant colitis complicating antibiotic-associated pseudomembranous colitis: case report and review of the clinical manifestations and treatment." Am J Gastroenterol 82 (1987): 374-7
  28. Burt RA "A review of the drug events reported by 12,917 patients treated with cephalexin." Postgrad Med J 59 (1983): 47-50,51-3
  29. Ring FA, Hershfield NB, Machin GA, Scott RB "Sulfasalazine-induced colitis complicating idiopathic ulcerative colitis." Can Med Assoc J 131 (1984): 43-5
  30. Friedman RJ, Mayer IE, Galambos JT, Hersh T "Oxacillin-induced pseudomembranous colitis." Am J Gastroenterol 73 (1980): 445-7
  31. "Multum Information Services, Inc. Expert Review Panel"
  32. Leigh DA, Simmons K, Williams S "Gastrointestinal side effects following clindamycin and lincomycin treatment: a follow up study." J Antimicrob Chemother 6 (1980): 639-45
  33. Hinton NA "The effect of oral tetracycline HCl and doxycycline on the intestinal flora." Curr Ther Res Clin Exp 12 (1970): 341-52
  34. Hecht JR, Olinger EJ "Clostridium difficile colitis secondary to intravenous vancomycin." Dig Dis Sci 34 (1989): 148-9
  35. Brause BD, Romankiewicz JA, Gotz V, Franklin JE Jr, Roberts RB "Comparative study of diarrhea associated with clindamycin and ampicillin therapy." Am J Gastroenterol 73 (1980): 244-8
  36. Saginur R, Hawley CR, Bartlett JG "Colitis associated with metronidazole therapy." J Infect Dis 141 (1980): 772-4
  37. Calandra GB, Brown KR, Grad LC, et al "Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin." Am J Med 78 (1985): 73-8
  38. Sugarman B "Trimethoprim-sulfamethoxazole, pseudomembranous colitis, and spinal cord injury." South Med J 78 (1985): 711-3
  39. Hutcheon DF, Milligan FD, Yardley JH, Hendrix TR "Cephalosporin-associated pseudomembranous colitis." Am J Dig Dis 23 (1978): 321-6
  40. Bingley PJ, Harding GM "Clostridium difficile colitis following treatment with metronidazole and vancomycin." Postgrad Med J 63 (1987): 993-4
  41. Golledge CL, Riley TV "Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis." Lancet 345 (1995): 1377-8
  42. Edlund C, Lidbeck A, Kager L, Nord CE "Effect of enoxacin on colonic microflora of healthy volunteers." Eur J Clin Microbiol 6 (1987): 298-300
  43. Midtvedt T, Carlstedt-Duke B, Hoverstad T, et al "Influence of peroral antibiotics upon the biotransformatory activity of the intestinal microflora in healthy subjects." Eur J Clin Invest 16 (1986): 11-7
  44. Altamirano A, Bondani A "Adverse reactions to furazolidone and other drugs. A comparative review." Scand J Gastroenterol Suppl 169 (1989): 70-80
  45. Boriello SP, Jones RH, Phillips I "Rifampicin-associated pseudomembranous colitis." Br Med J 281 (1980): 1180-1
  46. Klinger D, Radford P, Collin J "Pneumoperitoneum without faecal peritonitis in a patient with pseudomembranous colitis." Br Med J 288 (1984): 1271-2
  47. Edlund C, Brismar B, Nord CE "Effect of lomefloxacin on the normal oral and intestinal microflora." Eur J Clin Microbiol Infect Dis 1 (1990): 35-9
View all 47 references
Major

Beta-lactams (parenteral) (Includes Ceftin) ↔ renal dysfunction

Severe Potential Hazard, High plausibility. Applies to: Renal Dysfunction

Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites. The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function. Neurotoxic reactions, including encephalopathy, asterixis, myoclonus, seizures and coma, have been reported in such patients treated parenterally with these agents. Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling. Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.

References

  1. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC.
  2. Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974): 36-52
  3. Aronoff GR, Sloan RS, Stanish RA, Fineberg NS "Mezlocillin dose dependent elimination kinetics in renal impairment." Eur J Clin Pharmacol 21 (1982): 505-9
  4. Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 Suppl 1 (1985): s145-50
  5. Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR "Nephrotoxicity associated with cephalothin administration." Arch Intern Med 135 (1975): 797-801
  6. Al-Zahawi MF, Sprott MS, Hendrick DJ "Hallucinations in association with ceftazidime." Br Med J 297 (1988): 858
  7. "Product Information. Keflin (cephalothin)." Lilly, Eli and Company, Indianapolis, IN.
  8. Pazin GJ, Schwartz SN, Ho M, Lyon JA, Pasculle AW "Treatment of septicemic patients with cefoxitin: pharmacokinetics in renal insufficiency." Rev Infect Dis 1 (1979): 189-94
  9. Smith BR, LeFrock JL, Thyrum PT, et al "Cefotetan pharmacokinetics in volunteers with various degrees of renal function." Antimicrob Agents Chemother 29 (1986): 887-93
  10. Wade JC, Schimpff SC, Wiernik PH "Antibiotic combination - associated nephrotoxicity in granulocytopenic patients with cancer." Arch Intern Med 141 (1981): 1789-93
  11. Pasternak DP, Stephens BG "Reversible nephrotoxicity associated with cephalothin therapy." Arch Intern Med 135 (1975): 599-602
  12. Bundtzen RW, Toothaker RD, Nielson OS, et al "Pharmacokinetics of cefuroxime in normal and impaired renal function: comparison of high-pressure liquid chromatography and microbiological assays." Antimicrob Agents Chemother 19 (1981): 443-9
  13. Fillastre JP, Leroy A, Humbert G, Godin M "Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function." J Antimicrob Chemother 6 (1980): 103-11
  14. Kampf D, Schurig R, Korsukewitz I, Bruckner O "Cefoxitin pharmacokinetics: relation to three different renal clearance studies in patients with variuos degrees of renal insufficiency." Antimicrob Agents Chemother 20 (1981): 741-6
  15. Brogard JM, Comte F, Spach MO, Lavillaureix J "Pharmacokinetics of mezlocillin in patients with kidney impairment: special reference to hemodialysis and dosage adjustments in relation to renal function." Chemotherapy 28 (1982): 318-26
  16. Davies M, Morgan JR, Anand C "Administration of ticarcillin to patients with severe renal failure." Chemotherapy 20 (1974): 339-41
  17. McCloskey RV, Terry EE, McCracken AW, Sweeney MJ, Forland MF "Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium." Antimicrob Agents Chemother 1 (1972): 90-3
  18. Aronoff GR, Sloan RS, Brier ME, Luft FC "The effect of piperacillin dose on elimination kinetics in renal impairment." Eur J Clin Pharmacol 24 (1983): 543-7
  19. Blum RA, Kohli RK, Harrison NJ, Schentag JJ "Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis." Antimicrob Agents Chemother 33 (1989): 1470-6
  20. Hodgman T, Dasta JF, Armstrong DK, Visconti JA, Reilley TE "Ampicillin-associated seizures." South Med J 77 (1984): 1323-5
  21. Humbert G, Fillastre JP, Leroy A, Godin M, Van Winzum C "Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency." Rev Infect Dis 1 (1979): 118-26
  22. Burton JR, Lichtenstein NS, Colvin RB, Hyslop NE, Jr "Acute renal failure during cephalothin therapy." JAMA 229 (1974): 679-82
  23. Giron JA, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis." Antimicrob Agents Chemother 19 (1981): 279-83
  24. Welage LS, Schultz RW, Schentag JJ "Pharmacokinetics of ceftazidime in patients with renal insufficiency." Antimicrob Agents Chemother 25 (1984): 201-4
  25. Bergan T, Brodwall EK, Orjavik O "Pharmacokinetics of cefazolin in patients with normal and impaired renal function." J Antimicrob Chemother 3 (1977): 435-43
  26. "Product Information. Mefoxin (cefoxitin)." Merck & Co, Inc, West Point, PA.
  27. Meyers BR, Hirschman SZ "Pharmacokinetics of cefamandole in patients with renal failure." Antimicrob Agents Chemother 11 (1977): 248-50
  28. Wise R, Wright N, Wills PJ "Pharmacolgy of cefotaxime and its desacetyl metabolite in renal and hepatic disease." Antimicrob Agents Chemother 19 (1981): 526-31
  29. Mangione A, Boudinot FD, Schultz RM, Jusko WJ "Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment." Antimicrob Agents Chemother 21 (1982): 428-35
  30. Grcevska L, Polenakovic M "Second attack of acute tubulointerstitionephritis induced by cefataxim and pregnancy." Nephron 72 (1996): 354-5
  31. Fillastre JP, Leroy A, Godin M, Oksenhendler G, Humbert G "Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients." J Antimicrob Chemother 4 (1978): 79-83
  32. Fillastre JP, Leroy A, Baudoin C, et al "Pharmacokinetics of aztreonam in patients with chronic renal failure." Clin Pharmacokinet 10 (1985): 91-100
  33. "Product Information. Staphcillin (methicillin)." Apothecon Inc, Plainsboro, NJ.
  34. Madhavan T, Yaremchuk K, Levin N, et al "Effects of renal failure and dialysis on cefazolin pharmacokinetics." Antimicrob Agents Chemother 8 (1975): 63-6
  35. Brogard JM, Kopferschmitt J, Spach MO, et al "Cefamandole pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 19 (1979): 366-77
  36. Ohkawa M, Nakashima T, Shoda R, et al "Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis." Chemotherapy 31 (1985): 410-6
  37. Dubb J, Actor P, Pitkin D, et al "Ceftizoxime kinetics and renal handling." Clin Pharmacol Ther 31 (1982): 516-21
  38. Wright N, Wise R "The elimination of sulbactam alone and combined with ampicillin in patients with renal dysfunction." J Antimicrob Chemother 11 (1983): 583-7
  39. "Product Information. Mandol (cefamandole)." Lilly, Eli and Company, Indianapolis, IN.
  40. Sherman RA, Eisinger RP, Weinstein MP, Samel J "Cefoxitin-induced pseudo acute renal failure." Clin Ther 4 (1981): 114-7
  41. Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970): 57-9
  42. Klion AD, Kallsen J, Cowl CT, Nauseef WM "Ceftazidime-related nonconvulsive status epilepticus." Arch Intern Med 154 (1994): 586-9
  43. Haskell RJ, Fujita NK, Stevenson JA, Border WA "Cefoxitin-induced interstitial nephritis." Arch Intern Med 141 (1981): 1557
  44. "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome, Research Triangle Park, NC.
  45. Bechtel TP, Slaughter RL, Moore TD "Seizures associated with high cerebrospinal fluid concentrations of cefazolin." Am J Hosp Pharm 37 (1980): 271-3
  46. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb, Princeton, NJ.
  47. Walstad RA, Nilsen OG, Berg KJ "Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency." Eur J Clin Pharmacol 24 (1983): 391-8
  48. Lewis JA, Rindone JP "Acute interstitial nephritis associated with cephapirin." Drug Intell Clin Pharm 21 (1987): 380-1
  49. Czerwinski AW, Pederson JA, Barry JP "Cefazolin plasma concentrations and urinary excretion in patients with renal impairment." J Clin Pharmacol 14 (1974): 560-6
  50. Hardin TC, Butler SC, Ross S, Wakeford JH, Jorgensen JH "Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure - effects of differential pharmacokinetics on serum bactericidal activity." Pharmacotherapy 14 (1994): 147-52
  51. Benner EJ "Renal damage associated with prolonged administration of ampicillin, cephaloridine, and cephalothin." Antimicrob Agents Chemother 9 (1969): 417-20
  52. Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978): s88-97
  53. Oe PL, Simonian S, Verhoef J "Pharmacokinetics of the new penicillins." Chemotherapy 19 (1973): 279-88
  54. Ortiz A, Martin-Llonch N, Garron MP, et al "Cefazolin-induced encephalopathy in uremic patients." Rev Infect Dis 13 (1991): 772-3
  55. Goddard JK, Janning SW, Gass JS, Wilson RF "Cefuroxime-induced acute renal failure." Pharmacotherapy 14 (1994): 488-91
  56. Craig CP, Rifkin SI "Pharmacokinetics and hemodialyzability of cefazolin in uremic patients." Clin Pharmacol Ther 19 (1976): 825-9
  57. Alshohaib S, Satti MS, Abunijem Z "Acute interstitial nephritis due to cefotaxime." Nephron 73 (1996): 725
  58. Barriere SL, Gambertoglio JG, Alexander DR, et al "Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis." Rev Infect Dis 6 (1984): s809-15
  59. Czerwinski AW, Pederson JA "The pharmacology of cefamandole in patients with reduced renal function." Scand J Infect Dis 25 (1980): 45-8
  60. Pasmino P "Acute renal failure, skin rash, and eosinophilia associated with aztreonam." Am J Nephrol 8 (1988): 68-70
  61. Hansen MM, Kaaber K "Nephrotoxicity in combined cephalothin and gentamicin therapy." Acta Med Scand 201 (1977): 463-7
  62. Barrons RW, Murray KM, Richey RM "Populations at risk for penicillin-induced seizures." Ann Pharmacother 26 (1992): 26-9
  63. Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971): 41-6
  64. Wu MJ, Narsette TA, Hussey JL, Weinstein AB, Wen SF "Cephalothin neurotoxicity in renal failure." Ann Intern Med 89 (1978): 429
  65. Mellin H-E, Welling PG, Madsen PO "Pharmacokinetics of cefamandole in patients with normal and impaired renal function." Antimicrob Agents Chemother 11 (1977): 262-6
  66. al Shohaib S, Satti MS, Abunijem Z "Acute interstitial nephritis due to cefotaxime." Nephron 73 (1996): 725
  67. "Product Information. Ticar (ticarcillin)." SmithKline Beecham, Philadelphia, PA.
  68. Matzke GR, Abraham PA, Halstenson CE, Keane WF "Cefotaxime and desacetylcefotaxime kinetics in renal impairment." Clin Pharmacol Ther 38 (1985): 31-6
  69. Engle JE, Drago J, Carlin B, Schoolwerth AC "Letter: Reversible acute renal failure after cephalothin." Ann Intern Med 83 (1975): 232-3
  70. Welling PG, Craig WA, Bundtzen RW, et al "Pharmacokinetics of piperacillin in subjects with various degrees of renal function." Antimicrob Agents Chemother 23 (1983): 881-7
  71. Nielsen OS, Toothaker RD, Bundtzen RW, et al "Cefotaxime pharmacokinetics following a single intravenous dose to patients with varying renal function." Infection 8 (1980): s305-9
  72. Ohkawa M, Okasho A, Motoi I, et al "Elimination kinetics of cefotaxime and desacetylcefotaxime in patients with renal insufficiency and during hemodialysis." Chemotherapy 29 (1983): 4-12
  73. "Product Information. Cefadyl (cephapirin)." Apothecon Inc, Plainsboro, NJ.
  74. New PS, Wells CE "Cerebral toxicity associated with massive intravenous penicillin therapy." Neurology 15 (1965): 1053-8
  75. Rodjer S, Alestig K, Bergmark J, et al "Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects." J Antimicrob Chemother 20 (1987): 109-16
  76. Douglas MA, Quandt CM, Stanley DA "Ceftazidime-induced encephalopathy in a patient with renal impairment." Arch Neurol 45 (1988): 936-7
  77. Simpson IJ "Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine." N Z Med J 74 (1971): 312-5
  78. Blair AD, Maxwell BM, Forland SC, et al "Cefonicid kinetics in subjects with normal and impaired renal function." Clin Pharmacol Ther 35 (1984): 798-803
  79. Aronoff GR, Wolen RL, Obermeyer BD, Black HR "Pharmacokinetics and protein binding of cefamandole and its 1-methyl-1 H-tetrazole-5-thiol side chain in subjects with normal and impaired renal function." J Infect Dis 153 (1986): 1069-74
  80. Csanyi P, Rado JP, Hormay M "Acute renal failure due to cephamandole." Br Med J 296 (1988): 455
  81. "Product Information. Ancef (cefazolin)." SmithKline Beecham, Philadelphia, PA.
  82. Doluisio JT "Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function." Rev Infect Dis 4 Suppl (1982): s333-45
  83. Trang JM, Monson TP, Ackerman BH, et al "Effect of age and renal function on cefonicid pharmacokinetics." Antimicrob Agents Chemother 33 (1989): 142-6
  84. Parry MF, Neu HC "Pharmacokinetics of ticarcillin in patients with abnormal renal function." J Infect Dis 133 (1976): 46-9
  85. Mihindu JC, Scheld WM, Bolton ND, Spyker DA, Swabb EA, Bolton K "Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction." Antimicrob Agents Chemother 24 (1983): 252-61
  86. Bergan T, Orjavik O, Brodwall EK "Pharmacokinetics of cefapirin in patients with normal and impaired renal functions." Arzneimittelforschung 31 (1981): 1773-6
  87. Smith H, Lerner PI, Weinstein L "Neurotoxicity and "massive" intravenous therapy with penicillin." Arch Intern Med 120 (1967): 47-53
  88. Welling PG, Craig WA, Amidon GL, Kunin CM "Pharmacokinetics of cefazolin in normal and uremic subjects." Clin Pharmacol Ther 15 (1973): 344-53
  89. Ackerman BH, Ross J, Tofte RW, Rotschafer JC "Effect of decreased renal function on the pharmacokinetics of ceftazidime." Antimicrob Agents Chemother 25 (1984): 785-6
  90. Bulger RJ, Lindholm DD, Murray JS, Kirby WM "Effects of uremia on methicillin and oxacillin blood levels." JAMA 187 (1964): 319-22
  91. Kowalsky SF, Echols RM, Venezia AR, Andrews EA "Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function." Antimicrob Agents Chemother 24 (1983): 151-5
  92. Jackson GD, Berkovic SF "Ceftazidime encephalopathy: absence status and toxic hallucinations." J Neurol Neurosurg Psychiatry 55 (1992): 333-4
  93. Reitberg DP, Marble DA, Schultz RW, Whall TJ, Schentag JJ "Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis." Antimicrob Agents Chemother 32 (1988): 503-9
  94. Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA "Pharmacokinetics of cefepime in subjects with renal insufficiency." Clin Pharmacol Ther 48 (1990): 268-76
  95. Toll LL, Lee M, Sharifi R "Cefoxitin-induced interstitial nephritis." South Med J 80 (1987): 274-5
  96. "Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn, Kalamazoo, MI.
  97. Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972): 201-4
  98. Plaut ME, O'Connell CJ, Pabico RC, Davidson D "Penicillin handling in normal and azotemic patients." J Lab Clin Med 74 (1969): 12-8
  99. Bryan CS, Stone WJ ""Comparably massive" penicillin G therapy in renal failure." Ann Intern Med 82 (1975): 189-95
  100. Pickering MJ, Spooner GR, Quesada A, de Cade JR "Declining renal function associated with administration of cephalothin." South Med J 63 (1970): 426-8
  101. Chow M, Quintiliani R, Cunha BA, et al "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979): 185-94
  102. Pitkin D, Dubb J, Actor P, et al "Kinetics and renal handling of cefonicid." Clin Pharmacol Ther 30 (1981): 587-93
  103. Frimodt-Moller N, Maigaard S, Toothaker RD, et al "Mezlocillin pharmacokinetics after single intravenous doses to patients with various degrees of renal function." Antimicrob Agents Chemother 17 (1980): 599-607
  104. Czerwinski AW, Pederson JA "Pharmacokinetics of cefamandole in patients with renal impairment." Antimicrob Agents Chemother 15 (1979): 161-4
  105. Fillastre J-P, Fourtillan J-B, Leroy A, et al "Pharmacokinetics of cefonicid in uraemic patients." J Antimicrob Chemother 18 (1986): 203-11
  106. "Product Information. Monocid (cefonicid)." SmithKline Beecham, Philadelphia, PA.
  107. Brogard JM, Pinget M, Brandt C, Lavillaureix J "Pharmacokinetics of cefazolin in patients with renal failure: special reference to hemodialysis." J Clin Pharmacol 17 (1977): 225-30
  108. Martinez-Rodriguez JE, Barriga FJ, Santamaria J, et al. "Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure." Am J Med 111 (2001): 115-9
  109. Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978): s88-99
  110. Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979): 429-51
  111. Barrientos A, Bello I, Gutierrez-Millet V "Letter; Renal failure and cephalothin." Ann Intern Med 84 (1976): 612
  112. Reddy J, Bailey RR "Cefoxitin-associated renal failure." N Z Med J 93 (1981): 337-9
  113. Garcia MJ, Dominguez-Gil A, Tabernero JM, Tomero JA "Pharmacokinetics of cefoxitin in patients with normal or impaired renal function." Eur J Clin Pharmacol 16 (1979): 119-24
  114. Konishi K, Suzuki H, Hayashi M, Saruta T "Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function." J Antimicrob Chemother 31 (1993): 413-20
  115. "Product Information. Pfizerpen (penicillin)." Roerig Division, New York, NY.
  116. Wright N, Wise R, Hegarty T "Cefotetan elimination in patients with varying degrees of renal dysfunction." J Antimicrob Chemother 1 (1983): 213-6
  117. Kabins SA, Cohen S "Cephalothin serum levels in the azotemic patient." Antimicrob Agents Chemother 10 (1964): 207-14
  118. Arvidsson A, Borga O, Alvan G "Renal excretion of cephapirin and cephaloridine: evidence for saturable tubular reabsorption." Clin Pharmacol Ther 25 (1979): 870-6
  119. Pascual J, Liano F, Ortuno J "Cefotaxime-induced encephalopathy in an uremic patient." Nephron 54 (1990): 92
  120. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals, Wilmington, DE.
  121. Appel GB, Neu HC, Parry MF, et al "Pharmacokinetics of cefamandole in the presence of renal failure and in patients undergoing hemodialysis." Antimicrob Agents Chemother 10 (1976): 623-5
  122. Fanning WL, Gump D, Jick H "Gentamicin- and cephalothin-associated rises in blood urea nitrogen." Antimicrob Agents Chemother 10 (1976): 80-2
  123. Ings RM, Reeves DS, White LP, et al "The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination." J Pharmacokinet Biopharm 13 (1985): 121-42
  124. Palla R, Panichi V, Bionda A, et al "Acute renal failure after mezlocilline." Clin Nephrol 25 (1986): 315-6
  125. Jungbluth GL, Cooper DL, Doyle GD, Chudzik GM, Jusko WJ "Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function." Antimicrob Agents Chemother 30 (1986): 896-900
  126. Johnson CA, Halstenson CE, Kelloway JS, et al "Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease." Clin Pharmacol Ther 51 (1992): 32-41
  127. "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  128. Nguyen VD, Nagelberg H, Agarwal BN "Acute interstitial nephritis associated with cefotetan therapy." Am J Kidney Dis 16 (1990): 259-61
  129. van Dalen R, Vree TB, Baars AM, Termond E "Dosage adjustment for ceftazidime in patients with impaired renal function." Eur J Clin Pharmacol 30 (1986): 597-605
  130. Jusko WJ, Lewis GP, Schmitt GW "Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects." Clin Pharmacol Ther 14 (1972): 90-9
  131. Foord RD "Cephaloridine, cephalothin and the kidney." J Antimicrob Chemother 1 (1975): 119-33
  132. Bloomer HA, Barton LJ, Maddock RK "Penicillin-induced encephalopathy in uremic patients." JAMA 200 (1967): 121-3
  133. Phelps RT, Conte JE "Multiple-dose pharmacokinetics of cefonicid in patients with impaired renal function." Antimicrob Agents Chemother 29 (1986): 913-7
  134. Ohkawa M, Okasho A, Sugata T, Kuroda K "Elimination kinetics of ceftizoxime in humans with and without renal insufficiency." Antimicrob Agents Chemother 22 (1982): 308-11
  135. Smyth RD, Pfeffer M, Glick A, et al "Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin." Antimicrob Agents Chemother 16 (1979): 615-21
  136. "Product Information. Cefizox (ceftizoxime)." Fujisawa, Deerfield, IL.
  137. "Product Information. Claforan (cefotaxime)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  138. Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985): s145-50
  139. Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970): 57-9
  140. "Product Information. Pipracil (piperacillin)." Lederle Laboratories, Wayne, NJ.
  141. "Product Information. Tazicef (ceftazidime)." SmithKline Beecham, Philadelphia, PA.
  142. Thompson MI, Russo ME, Matsen JM, Atkin-Thor E "Piperacillin pharmacokinetics in subjects with chronic renal failure." Antimicrob Agents Chemother 19 (1981): 450-3
  143. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC.
  144. Ohkawa M, Hirano S, Tokunaga S, et al "Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function." Antimicrob Agents Chemother 23 (1983): 31-5
  145. Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Halstenson CE, Opsahl JA, Pittman KA "Disposition of the cephalosporin cefepime in normal and renally impaired subjects." Drug Metab Dispos 19 (1991): 68-73
  146. Ings RM, Fillastre J-P, Godin M, et al "The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function." Rev Infect Dis 4 (1982): s379-91
  147. Nilsson-Ehle I, Nilsson-Ehle P "Pharmacokinetics of cephalothin: accumulation of its deacetylated metabolite in uremic patients." J Infect Dis 139 (1979): 712-6
  148. Trollfors B, Ahlmen J, Alestig K "Renal function during cefoperazone treatment." J Antimicrob Chemother 9 (1982): 485-7
  149. Leroy J, Leguy F, Borsa F, et al "Pharmacokinetics of ceftazidime in normal and uremic subjects." Antimicrob Agents Chemother 25 (1984): 638-42
  150. Walstad RA, Dahl K, Hellum KB, et al "The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy." Eur J Clin Pharmacol 35 (1988): 273-9
  151. Hillsley RE, Massey EW "Truncal asterixis associated with ceftazidime, a third-generation cephalosporin." Neurology 41 (1991): 2008
  152. Slaker RA, Danielson B "Neurotoxicity associated with ceftazidime therapy in geriatric patients with renal dysfunction." Pharmacotherapy 11 (1991): 351-2
  153. Mackie K, Pavlin EG "Recurrent paralysis following piperacillin administration." Anesthesiology 72 (1990): 561-3
View all 153 references
Moderate

Cefuroxime (Includes Ceftin) ↔ ferricyanide tests

Moderate Potential Hazard, High plausibility. Applies to: Diabetes Mellitus

Cefuroxime may cause false-negative reactions for blood/plasma glucose with the ferricyanide test, but not with tests using glucose oxidase or hexokinase. Clinicians should be cognizant of this interaction when prescribing or administering cefuroxime to patients with diabetes.

References

  1. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC.
  2. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC.
Moderate

Cefuroxime (Includes Ceftin) ↔ sodium

Moderate Potential Hazard, High plausibility. Applies to: Congestive Heart Failure, Hypertension, Fluid Retention, Hypernatremia

Parenteral cefuroxime sodium contains approximately 55 mg (2.4 mEq) of sodium per each gram of cefuroxime activity. The frozen solutions of cefuroxime sodium are additionally formulated with sodium citrate hydrous as a buffer and contain approximately 110 mg (4.8 mEq) and 223 mg (9.7 mEq) of sodium in the 750 mg and 1.5 g doses, respectively. The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.

References

  1. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC.
Moderate

Cephalosporins (Includes Ceftin) ↔ dialysis

Moderate Potential Hazard, High plausibility. Applies to: hemodialysis

Most cephalosporin antibiotics are removed by hemodialysis. Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis. Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.

References

  1. Barriere SL, Gambertoglio JG, Alexander DR, et al "Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis." Rev Infect Dis 6 (1984): s809-15
  2. "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn, Kalamazoo, MI.
  3. Chodos J, Francke EL, Saltzman M, Neu HC "Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis." Ther Drug Monit 3 (1981): 71-4
  4. Nikolaidis P, Tourkantonis A "Effect of hemodialysis on ceftazidime pharmacokinetics." Clin Nephrol 24 (1985): 142-6
  5. "Product Information. Claforan (cefotaxime)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  6. Aziz NS, Gambertoglio JG, Lin ET, Grausz H, Benet LZ "Pharmacokinetics of cephalothin and its metabolite in uremic patients undergoing hemodialysis using an HPLC assay." Jernal Perubatan UKM (Medical Journal, National Univ. of Malaysia) 2 (2) (1980): 82-9
  7. "Product Information. Cedax (ceftibuten)." Schering-Plough, Liberty Corner, NJ.
  8. "Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb, Princeton, NJ.
  9. Allaouchiche B, Breilh D, Jaumain H, Gaillard B, Renard S, Saux MC "Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration." Antimicrob Agents Chemother 41 (1997): 2424-7
  10. Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988): 261-6
  11. Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971): 540-3
  12. Appel GB, Neu HC, Parry MF, et al "Pharmacokinetics of cefamandole in the presence of renal failure and in patients undergoing hemodialysis." Antimicrob Agents Chemother 10 (1976): 623-5
  13. "Product Information. Tazicef (ceftazidime)." SmithKline Beecham, Philadelphia, PA.
  14. Ohkawa M, Okasho A, Motoi I, et al "Elimination kinetics of cefotaxime and desacetylcefotaxime in patients with renal insufficiency and during hemodialysis." Chemotherapy 29 (1983): 4-12
  15. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC.
  16. Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979): 465-70
  17. "Product Information. Velosef (cephradine)." Apothecon Inc, Plainsboro, NJ.
  18. Browning MJ, Holt HA, White LO, et al "Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis." J Antimicrob Chemother 18 (1986): 103-6
  19. Spyker DA, Gober LL, Scheld WM, et al "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982): 278-81
  20. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb, Princeton, NJ.
  21. Shyu WC, Pittman KA, Wilber RB, et al "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991): 362-71
  22. Spyker DA, Richmond JD, Scheld WM, Bolton WK "Pharmacokinetics of multiple-dose cefoperazone in hemodialysis patients." Am J Nephrol 5 (1985): 355-60
  23. Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984): 83-7
  24. "Product Information. Omnicef (cefdinir)." Parke-Davis, Morris Plains, NJ.
  25. Kroh UF, Lennartz H, Edwards DJ, Stoeckel K "Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration." J Clin Pharmacol 36 (1996): 1114-9
  26. "Product Information. Ancef (cefazolin)." SmithKline Beecham, Philadelphia, PA.
  27. Hasegawa H, Imada A, Horiuchi A, et al "Pharmacokinetics of cefotaxime in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis." J Antimicrob Chemother 14 Suppl (1984): 135-42
  28. "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc, Deerfield, IL.
  29. "Product Information. Rocephin (ceftriaxone)." Roche Laboratories, Nutley, NJ.
  30. "Product Information. Keflin (cephalothin)." Lilly, Eli and Company, Indianapolis, IN.
  31. Garcia MJ, Dominguez-Gil A, Tabernero JM, Roman AB "Pharmacokinetics of cefoxitin in patients undergoing hemodialysis." Int J Clin Pharmacol Biopharm 17 (1979): 366-70
  32. Garcia MJ, Dominguez-Gil A, Tabernero JM, Molina MD "Pharmacokinetics of cefoxitin during haemofiltration." Eur J Clin Pharmacol 25 (1983): 395-8
  33. Campillo JA, Lanao JM, Dominguez-Gil A, et al "Pharmacokinetics of cefamandole in patients undergoing hemodialysis." Int J Clin Pharmacol Biopharm 17 (1979): 416-20
  34. McCloskey RV, Terry EE, McCracken AW, Sweeney MJ, Forland MF "Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium." Antimicrob Agents Chemother 1 (1972): 90-3
  35. Gambertoglio JG, Aziz NS, Lin ET, et al "Cefamandole kinetics in uremic patients undergoing hemodialysis." Clin Pharmacol Ther 26 (1979): 592-9
  36. "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company, Indianapolis, IN.
  37. "Product Information. Cefadyl (cephapirin)." Apothecon Inc, Plainsboro, NJ.
  38. Davis GM, Forland SC, Cutler RE "Serum and dialysate concentrations of cephalexin following repeated dosing in CAPD patients." Am J Kidney Dis 6 (1985): 177-80
  39. Matzke GR, Frye RF, Joy MS, Palevsky PM "Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis." Pharmacotherapy 20 (2000): 635-43
  40. Gabutti L, Taminelli-Beltraminelli L, Marone C "Clearance of ceftriaxone during haemodialysis using cuprophane, haemophane and polysulfone dialysers." Eur J Clin Pharmacol 53 (1997): 123-6
  41. Berman SJ, Boughton WH, Sugihara JG, et al "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978): 281-3
  42. "Product Information. Keflex (cephalexin)." Dista Products Company, Indianapolis, IN.
  43. Craig CP, Rifkin SI "Pharmacokinetics and hemodialyzability of cefazolin in uremic patients." Clin Pharmacol Ther 19 (1976): 825-9
  44. Bunke CM, Aronoff GR, Brier ME, et al "Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis." Clin Pharmacol Ther 33 (1983): 66-72
  45. Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990): 157-62
  46. Gabutti L, TaminelliBeltraminelli L, Marone C "Clearance of ceftriaxone during haemodialysis using cuprophane, haemophane and polysulfone dialysers." Eur J Clin Pharmacol 53 (1997): 123-6
  47. Brogard JM, Pinget M, Brandt C, Lavillaureix J "Pharmacokinetics of cefazolin in patients with renal failure: special reference to hemodialysis." J Clin Pharmacol 17 (1977): 225-30
  48. "Product Information. Mandol (cefamandole)." Lilly, Eli and Company, Indianapolis, IN.
  49. Weiss LG, Cars O, Danielson BG, et al "Pharmacokinetics of intravenous cefuroxime during intermittent and continuous arteriovenous hemofiltration." Clin Nephrol 30 (1988): 282-6
  50. "Product Information. Cefizox (ceftizoxime)." Fujisawa, Deerfield, IL.
  51. Ohkawa M, Nakashima T, Shoda R, et al "Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis." Chemotherapy 31 (1985): 410-6
  52. "Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb, Princeton, NJ.
  53. Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970): 60-4
  54. Bunke CM, Aronoff GR, Luft FC "Pharmacokinetics of common antibiotics used in continuous ambulatory peritoneal dialysis." Am J Kidney Dis 3 (1983): 114-7
  55. "Product Information. Lorabid (loracarbef)." Lilly, Eli and Company, Indianapolis, IN.
  56. "Product Information. Monocid (cefonicid)." SmithKline Beecham, Philadelphia, PA.
  57. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals, Wilmington, DE.
  58. Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983): 529-32
  59. Madhavan T, Yaremchuk K, Levin N, et al "Effects of renal failure and dialysis on cefazolin pharmacokinetics." Antimicrob Agents Chemother 8 (1975): 63-6
  60. Johnson CA, Ateshkadi A, Zimmerman SW, Hughes GS, Craig WA, Carey PM, Borin MT "Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis." Antimicrob Agents Chemother 37 (1993): 2650-5
  61. "Product Information. Cefobid (cefoperazone)." Roerig Division, New York, NY.
  62. "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc, Baltimore, MD.
  63. "Product Information. Mefoxin (cefoxitin)." Merck & Co, Inc, West Point, PA.
  64. Ahern MJ, Finkelstein FO, Andriole VT "Pharmacokinetics of cefamandole in patients undergoing hemodialysis and peritoneal dialysis." Antimicrob Agents Chemother 10 (1976): 457-61
View all 64 references
Moderate

Cephalosporins (Includes Ceftin) ↔ liver disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Cases of hepatitis have been reported with the use of certain cephalosporins. Transient rise in SGOT, SGPT, and alkaline phosphatase levels have also been observed. Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.

Moderate

Cephalosporins (Includes Ceftin) ↔ seizure disorders

Moderate Potential Hazard, Moderate plausibility. Applies to: Seizures

Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures occur with drug therapy, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated. Monitor patients with preexisting seizure disorders.

Ceftin (cefuroxime) drug interactions

There are 126 drug interactions with Ceftin (cefuroxime)

Ceftin (cefuroxime) alcohol/food interactions

There is 1 alcohol/food interaction with Ceftin (cefuroxime)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide